gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
July 06 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
bioelectronic medicine and wellness company, today announced that
its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has
been selected to be a part of studies on effects of cannabinoids
and alternative care on athlete pain management and performance.
The NFL and NFLPA are jointly awarding two research grants to
independent medical researchers at the American Society of Pain and
Neuroscience (ASPN) and Emory University.
The grants will fund investigations into innovative,
first-of-their-kind, alternative pain management methods that could
benefit NFL players, and society at large. These awards are the
second round chosen by the NFL-NFLPA Joint Pain Management
Committee (PMC), which aims to facilitate research to better
understand and improve potential alternative pain management
treatments for NFL players.
nVNS will be used in “A Pilot Study Assessing Non-Invasive
Treatment of Refractory Post-Concussion Headache Pain," led by Dr.
Erika Petersen and researchers at the American Society of Pain and
Neuroscience (ASPN). The randomized study will compare nVNS and
cannabidiol (CBD) in contact sport athletes experiencing
Post-Traumatic Headache (PTH) to current standard of care
treatment.
PTH is one of the most common aftereffects of concussion or
other traumatic brain injury. PTH is a poorly treated, highly
debilitating headache disorder where medications and other options
for treatment are not very effective. Given that nearly 4 million
Americans are diagnosed with concussions annually, PTH should be
considered a substantial public health concern. The pilot data
gathered in this study will guide future investigations into
treatment of patients with post-traumatic headache.
“We are thrilled to have been selected to be part of a study
that focuses on alternative care options for pain management and
performance,” said Dr. Peter Staats, Chief Medical Officer at
electroCore. “Post-Traumatic Headache as an area of focus for
electroCore is a natural progression from our cleared indications
in primary headache. We are hopeful that nVNS will prove to be a
pain management option for athletes, military personnel, or anyone
suffering from pain associated with PTH.”
About the NFL-NFLPA Joint Pain Management
CommitteeThe Joint Pain Management Committee is comprised
of medical experts appointed by the league and the NFLPA. The
Committee works to establish uniform standards for club practices
and policies regarding pain management and the use of prescription
medications by NFL players.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About gammaCore™gammaCore™ (nVNS) is the first
non-invasive, hand-held medical therapy applied at the neck to
treat migraine and cluster headache through the utilization of a
mild electrical stimulation to the vagus nerve that passes through
the skin. Designed as a portable, easy-to-use technology, gammaCore
is self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore™ is intended to provide non-invasive vagus nerve
stimulation (nVNS) on the side of the neck for preventive treatment
of migraine and the acute treatment of pain associated with
migraine in patients 12 and older. gammaCore is also indicated for
adjunctive use for preventive treatment of cluster headache, acute
treatment of episodic cluster headache, and treatment of hemicrania
continua and paroxysmal hemicrania in adult patients. gammaCore
should not be used by people with an active implantable medical
device. Please refer to gammaCore.com or the Instructions for Use
for complete safety information, including indications,
contraindications, warnings, cautions, and instructions.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, but are not limited
to, statements regarding the results from work being conducted as
part of the two research grants to independent medical researchers
at the American Society of Pain and Neuroscience (ASPN) and Emory
University on effects of cannabinoids and alternative care on
athlete pain management and performance, statements about
electroCore's business prospects and clinical and product
development plans; its pipeline or potential markets for its
technologies, electroCore's business prospects, its sales and
marketing and product development plans, future cash flow
projections, anticipated costs, its product portfolio or potential
markets for its technologies, the availability and impact of payor
coverage, the potential of nVNS generally and gammaCore nVNS in
particular to concussion and PTH, and other statements that are not
historical in nature, particularly those using terminology such as
"anticipates," "expects," "believes," "intends," other words of
similar meaning, derivations of such words and the use of future
dates. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to obtain additional financing
necessary to continue electroCore's business, sales and marketing
and product development plans, the uncertainties inherent in the
development of new products or technologies, the ability to
successfully commercialize TAC-STIM™, competition in the industry
in which electroCore operates and general market conditions. The
results of earlier preclinical studies and clinical trials may not
be predictive of results of future preclinical studies, clinical
trials, or commercial success. All forward-looking statements are
made as of the date of this press release, and electroCore
undertakes no obligation to update forward-looking statements or to
update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law. Investors should refer to all information set forth in this
document and should also refer to the disclosure of risk factors
set forth in the reports and other documents electroCore files with
the SEC, available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024